Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lamotrigine therapeutic thresholds.

Marianne Søndergaard Khinchi1, Kirsten Annette Nielsen, Marit Dahl

  • 1Danish Epilepsy Centre, 1 Kolonivej, Dianalund, Denmark.

Seizure
|January 9, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic Yield and Clinical Impact of Comprehensive WES/WGS Testing Beyond Common Genetic Causes in Hereditary Optic Atrophy.

Clinical genetics·2026
Same author

Clobazam versus corticosteroid for developmental and epileptic encephalopathy with spike-wave activation in sleep ((D)EE-SWAS): Results of a multicenter observational study.

Epilepsia·2025
Same author

Unmasking the role of the occipital lobe in epilepsy with eyelid myoclonia.

Epilepsia·2025
Same author

High-Resolution Spatial Map of the Human Facial Sebaceous Gland Reveals Marker Genes and Decodes Sebocyte Differentiation.

The Journal of investigative dermatology·2025
Same author

Associations of Thyroid and Parathyroid Hormones with Arterial Stiffness in Emergency Department Patients: A Prospective Cross-Sectional Study.

Medicina (Kaunas, Lithuania)·2025
Same author

Urocanase-Positive Skin-Resident Bacteria Metabolize cis-Urocanic Acid and in Turn Reduce the Immunosuppressive Properties of UVR.

The Journal of investigative dermatology·2025
Same journal

UNC13A-related neurodevelopmental disorders in children: epilepsy phenotypes and antiseizure medication response.

Seizure·2026
Same journal

Switching from oxcarbazepine to eslicarbazepine in patients with focal epilepsy: A systematic review and single-arm meta-analysis.

Seizure·2026
Same journal

Efficacy, tolerability, and EEG lateralization-based predictors of neuropsychiatric adverse events in pediatric SeLECTS treated with perampanel monotherapy.

Seizure·2026
Same journal

Cross-cultural validation of the International Classification of Cognitive Disorders in Epilepsy (IC-CoDE) in Chinese-speaking people with epilepsy.

Seizure·2026
Same journal

Unlocking seizure freedom: A European Delphi panel study on the clinical, humanistic, and economic value of seizure control in epilepsy.

Seizure·2026
Same journal

RLIM variant associated with X-linked epilepsy with neurodevelopmental disorders and the molecular sub-regional effects.

Seizure·2026
See all related articles

Therapeutic drug monitoring (TDM) for lamotrigine (LTG) helps establish individual therapeutic thresholds (TT) in epilepsy patients. This approach aids in optimizing LTG treatment by identifying personalized effective and safe drug levels.

Area of Science:

  • Pharmacology
  • Clinical Neurology
  • Epilepsy Management

Background:

  • Lamotrigine (LTG) is a widely used antiepileptic drug.
  • Optimizing LTG dosage is crucial for seizure control and minimizing adverse effects.
  • Individualized therapeutic thresholds (TT) may improve treatment efficacy.

Purpose of the Study:

  • To evaluate therapeutic drug monitoring (TDM) for lamotrigine (LTG).
  • To establish individual therapeutic thresholds (TT) in epilepsy outpatients on LTG monotherapy.
  • To assess the utility of TDM in a tertiary epilepsy center.

Main Methods:

  • Retrospective analysis of 82 outpatients on LTG monotherapy at the Danish Epilepsy Centre.
  • Identification of seizure-free patients with no adverse reactions in the last 6 months.

Related Experiment Videos

  • Calculation of individual TT using plasma LTG levels from routine TDM during up-titration.

    • Main Results:

    • Therapeutic thresholds (TT) varied widely (4.0–42.0 micromol/l) among 48 evaluable patients.
    • A significant portion (34/82) achieved seizure freedom on initial LTG doses, precluding TT calculation.
    • No significant differences in TT were observed between pediatric and adult patients or epilepsy types.

    Conclusions:

    • A minority of epilepsy patients require high LTG therapeutic levels, suggesting potential for toxicity in some cases.
    • Therapeutic drug monitoring (TDM) is valuable for establishing individual reference ranges for LTG.
    • TDM aids in identifying the individual level-to-dose ratio, optimizing lamotrigine treatment.